Anavex Life Sciences Corp.
AVXL
$9.53
-$0.02-0.21%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 61.17% | -9.46% | 16.78% | 7.23% | -14.04% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.81% | 2.18% | 22.20% | 13.80% | 8.57% |
| Operating Income | -1.81% | -2.18% | -22.20% | -13.80% | -8.57% |
| Income Before Tax | -8.42% | -6.16% | -40.47% | -15.02% | -8.68% |
| Income Tax Expenses | -- | -- | -- | -93.75% | -- |
| Earnings from Continuing Operations | -8.42% | -6.16% | -40.47% | -14.53% | -8.28% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.42% | -6.16% | -40.47% | -14.53% | -8.28% |
| EBIT | -1.81% | -2.18% | -22.20% | -13.80% | -8.57% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -7.34% | -2.89% | -36.00% | -10.66% | -3.58% |
| Normalized Basic EPS | -7.31% | -3.00% | -35.92% | -10.67% | -3.91% |
| EPS Diluted | -7.34% | -2.89% | -36.00% | -10.66% | -3.58% |
| Normalized Diluted EPS | -7.31% | -3.00% | -35.92% | -10.67% | -3.91% |
| Average Basic Shares Outstanding | 1.00% | 3.16% | 3.32% | 3.44% | 4.53% |
| Average Diluted Shares Outstanding | 1.00% | 3.16% | 3.32% | 3.44% | 4.53% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |